Ongoing trials further support in refractory SLE/LN to target the type I/I IFN JAK/STAT pathway (e.g., tofacitinib), to deplete tissular B cells ± plasmocytes (CAR T cells and obinituzimab instead of rituximab), or to deplete CD38-positive plasmocytes (daratumab) [130]. The gene discussed is CD38; the disease is systemic lupus erythematosus.